Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Casey A. Maguire, Ph.D.


This page shows the publications co-authored by Casey Maguire and Bakhos Tannous.
Connection Strength

  1. Mouse gender influences brain transduction by intravascularly administered AAV9. Mol Ther. 2013 Aug; 21(8):1470-1.
    View in: PubMed
    Score: 0.529
  2. Triple bioluminescence imaging for in vivo monitoring of cellular processes. Mol Ther Nucleic Acids. 2013 Jun 18; 2:e99.
    View in: PubMed
    Score: 0.525
  3. Codon-optimized Luciola italica luciferase variants for mammalian gene expression in culture and in vivo. Mol Imaging. 2012 Feb; 11(1):13-21.
    View in: PubMed
    Score: 0.477
  4. Gaussia luciferase variant for high-throughput functional screening applications. Anal Chem. 2009 Aug 15; 81(16):7102-6.
    View in: PubMed
    Score: 0.402
  5. Systemically administered AAV9-sTRAIL combats invasive glioblastoma in a patient-derived orthotopic xenograft model. Mol Ther Oncolytics. 2016; 3:16017.
    View in: PubMed
    Score: 0.162
  6. Intracranial AAV-sTRAIL combined with lanatoside C prolongs survival in an orthotopic xenograft mouse model of invasive glioblastoma. Mol Oncol. 2016 Apr; 10(4):625-34.
    View in: PubMed
    Score: 0.156
  7. Heparin affinity purification of extracellular vesicles. Sci Rep. 2015 May 19; 5:10266.
    View in: PubMed
    Score: 0.150
  8. Directed molecular evolution reveals Gaussia luciferase variants with enhanced light output stability. Anal Chem. 2013 Mar 05; 85(5):3006-12.
    View in: PubMed
    Score: 0.128
  9. Sensitive assay for mycoplasma detection in mammalian cell culture. Anal Chem. 2012 May 01; 84(9):4227-32.
    View in: PubMed
    Score: 0.121
  10. Microvesicle-associated AAV vector as a novel gene delivery system. Mol Ther. 2012 May; 20(5):960-71.
    View in: PubMed
    Score: 0.119
  11. Gene therapy for tuberous sclerosis complex type 2 in a mouse model by delivery of AAV9 encoding a condensed form of tuberin. Sci Adv. 2021 01; 7(2).
    View in: PubMed
    Score: 0.055
  12. Long-Term Therapeutic Efficacy of Intravenous AAV-Mediated Hamartin Replacement in Mouse Model of Tuberous Sclerosis Type 1. Mol Ther Methods Clin Dev. 2019 Dec 13; 15:18-26.
    View in: PubMed
    Score: 0.050
  13. Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter. ACS Nano. 2014 Jan 28; 8(1):483-494.
    View in: PubMed
    Score: 0.034
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.